Clinical Impact of 18F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience

Document Type : Original Article


1 King Hussein Cancer Center

2 Department of Radiology & Nuclear Medicine, Jordan University hospital, Amman, Jordan

3 Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan

4 Department of Radiology, King Hussein Cancer Center, Amman, Jordan


Objective(s): We aim to investigate the clinical impact of 18F-FDG PET/CT in managing patients with gynecological malignancies and pelvic or extrapelvic lymph nodes that are of equivocal significance on conventional imaging.
Methods: We retrospectively evaluated 18F-FDG PET/CT scans of patients with gynecologic tumors who were referred to King Hussein Cancer Center from January 2010 to August 2014. PET/CT results were compared with MRI and CT findings. We evaluated sensitivity and specificity of 18F-FDG PET/CT, its role in changing treatment plan
and its positive predictive value (PPV) and negative predictive value (NPV).
Results: Ninety seven patients (mean age: 49 years) underwent 18F-FDG/PET in the study period (40 cervical, 37 endometrial and 20 ovarian cancers). PET/CT scan provided additional information in 23 patients; upstaging 4.1% (4 patients; 3 true positive) and down staging in 19.5% (19 patients; 15 true negative). As a result, treatment strategy was changed from curative to palliative in three patients, and modification of radiation field or additional curative therapy was implemented following exclusion of distant metastasis in 11 patients. Mean follow up time for the whole cohort was 35 months (range 6 - 60 months). NPV of 18F-FDG PET/CT in detecting extrapelvic lymphadenopathy was 83.3%.
Conclusion: 18F-FDG PET/CT has high clinical impact in management of gynaecological cancers as it alters the treatment plan in a substantial number of patients who had equivocal findings on conventional imaging,
as well as it offers excellent validity in lymph nodes staging.


Main Subjects

1. Perroy A, Kotz H. Cervical cancer. The Bethesda handbook of clinical oncology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010. P. 241-51.
2. Key statistics about ovarian cancer. American Cancer Society. Available at: URL: http://www. ovarian-cancer-key-statistics; 2016.
3. Nimiri O. Cancer incidence in Jordan. Jordan: NonCommunicable Diseases Directorate, Jordan Cancer Registry. Ministry of Health; 2012.
4. FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125(2):97-8.
5. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1-5.
6. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107-8.
7. Suppiah S, Kamal SH, Mohd Zabid AZ, Abu Hassan H. Characterization of adnexal masses using multidetector contrast-enhanced CT scan– recognising common pitfalls that masquerade as ovarian cancer. Pertanika J Sci Technol. 2017;25(1):337-52.
8. Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651–Gynecologic Oncology Group 183. J Clin Oncol. 2005;23(36):9329-37.
9. Magné N, Chargari C, Vicenzi L, Gillion N, Messai T, Magné J, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG–PET. Cancer Treat Rev. 2008;34(8):671-81.
10. Musto A, Grassetto G, Marzola MC, Chondrogiannis S, Maffione AM, Rampin L, et al. Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature. Yonsei Med J. 2014;55(6):1467-72.
11. Rockall AG, Cross S, Flanagan S, Moore E, Avril N. The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging. 2012;12:49-65.
12. Cihoric N, Tapia C, Krüger K, Aebersold DM, Klaeser B, Lössl K. IMRT with 18 FDG-PETCT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol. 2014;9:83.
13. Salem A, Salem AF, Al-Ibraheem A, Lataifeh I, Almousa A, Jaradat I. Evidence for the use PET for radiation therapy planning in patients with cervical cancer: a systematic review. Hematol Oncol Stem Cell Ther. 2011;4(4):173-81.
14. Sironi S, Buda A, Picchio M, Perego P, Moreni R, Pellegrino A, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT 1. Radiology. 2006;238(1):272-9.
15. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Canc Netw. 2013;11(3):320-43.
16. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014;12(2):248-80.
17. Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24(4):889-901.
18. Signorelli M, Guerra L, Pirovano C, Crivellaro C, Fruscio R, Buda A, et al. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol. 2013;131(2):395-9.
19. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535-40.
20. Brockbank E, Kokka F, Bryant A, Pomel C, Reynolds K. Pretreatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev. 2013;3:CD008217.
21. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systemic lymphadnectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2010;20(4):520-8.
22. Wright JD, Huang Y, Burke WM, Tegas AI, Hou JY, Hu JC, et al. Influence of lymphadenectomy on survival for early stage-endometrial cancer. Obstet Gynecol. 2016;127(1):109-18.
23. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose–positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2010;77(4):1085-91.